Abstract
This Practice Point commentary discusses a meta-analysis by Strippoli et al. that included 50 randomized and quasi-randomized trials of statins in patients with different stages of kidney disease (predialysis, dialysis and transplantation; n = 30,144). The authors found that statins safely reduced lipid concentrations and the risk of cardiovascular events and cardiovascular mortality, but that the agents had no effect on all-cause mortality overall and had uncertain renoprotective effects. The analysis was comprehensive and well executed. A decreased risk of all-cause mortality with statins was found in studies of predialysis patients but not in studies of renal transplant recipients or patients on chronic dialysis. Statin doses used in the trials were well tolerated and safe in all subgroups of patients with chronic kidney disease; therefore, we feel that statin use to maintain LDL cholesterol below 100 mg/dl (2.6 mmol/l) should be initiated to potentially decrease cardiovascular risk in such patients. The benefits of statin therapy on all-cause mortality and the clinically significant benefits of this treatment on progression of kidney disease are still unclear, and additional trial evidence in patients with chronic kidney disease is needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Strippoli G et al. (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ 336: 645–651
Wanner C et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248
Tonelli M et al. (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557–1563
Collins R et al. (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361: 2005–2016
Shepherd J et al. (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Clin J Am Soc Nephrol 2: 1131–1139
Tonelli M et al. (2003) Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605–1613
Sandhu S et al. (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17: 2006–2016
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bogaert, Y., Chonchol, M. Assessing the benefits and harms of statin treatment in patients with chronic kidney disease. Nat Rev Nephrol 4, 470–471 (2008). https://doi.org/10.1038/ncpneph0892
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0892